Product Images Anastrozole
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Anastrozole NDC 68001-155 by Bluepoint Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Anastrozole Structural Formula - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 01
Figure 1 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 02
This appears to be a graph showing Disease-free survival in months for two different treatments - tamodfen and anastrozole. The graph shows the proportion of patients alive and free of disease over time (in months). The x-axis shows the months, whereas the y-axis shows the proportion of patients alive and disease-free. However, there is some missing information and unclear characters in the text which make it difficult to interpret the graph fully.*
Figure 2 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 03
This is a chart displaying the proportion of patients who were alive and free of disease during a randomized treatment. Two drugs were tested, tmodfen and amoxfen, and the chart shows the disease-free survival in months. The number of patients who were still at risk is shown on the right, organized by treatment (anastrozole vs anasromole) and time period.*
Figure 3 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 04
This text provides a graph (Figure 3) of the Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC Trial. The graph shows the proportion of event-free months from 0 to 114 months, with randomized treatment (anastrozole and tamoxifen) labeled on the horizontal axis and the time to event (months) labeled on the vertical axis. The number of patients at risk is shown for each treatment category. The vertical axis has been truncated for the improved clarity of the Kaplan-Meier curves.*
Figure 4 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 05
This figure (Figure 4) represents the Kaplan-Meier curves for disease-free survival in the hormone receptor-positive subpopulation of patients who were enrolled in the ATAC Trial and randomized to receive either anastrozole or tamoxifen monotherapy. The Kaplan-Meier curves are truncated to improve the clarity of the graph. The results are presented as a function of time to event in months, and the number of patients at risk are also reported.*
Figure 5 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 06
This is a graph representing the time to progression in months for randomized treatment of two drugs - Anastrozole and Tamoxifen. The x-axis shows the months from 0 to 32 and the y-axis represents the number of patients at risk. The graph shows that Anastrozole is more effective than Tamoxifen in reducing the progression of the disease. However, no additional information is available.*
Figure 6 - 3cd04ed6 7c5a 4c4a 9955 ee40839dfea0 07
This is a graph showing the time to progression in months for randomized treatment with anastrozole and tamoxifen. The x-axis shows the number of months and the y-axis shows the proportion not progressing. The graph is divided into two sections, one for randomized treatment with anastrozole and the other for tamoxifen. The data shows that anastrozole has a higher proportion not progressing than tamoxifen.*
Anastrozole Tablets 1mg 30ct Rev 09-17 - Anastrozole Tablets 1mg 30 tablets Rev 0913
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.